Pfizer the latest pharma to befriend Iktos for its AI drug discovery platform

Virtual drug design tech firm Iktos has set up a new pact with Big Pharma Pfizer to tap its artificial intelligence for its discovery work.

Pfizer will use the Paris-based company’s tech for de novo design to “selected Pfizer small-molecule discovery programs,” although the pair did not share specifics of the targets nor of any financials for the pact.